Williams A R, Turkie W H
Department of Medical Biophysics, University of Manchester Medical School, England.
Curr Med Res Opin. 1996;13(8):457-64. doi: 10.1185/03007999609115226.
RW94 is a permitted additive in the food industry, which precipitates fatty acids in vitro. In vivo, this could result in reduced fatty acid absorption by the body, and may, therefore, influence the amount of fat excreted in the faeces. An investigation into the effects of RW94 on bodily fat absorption and excretion was undertaken. The safety, tolerability and efficacy of the product was compared with placebo in a group of 12 healthy volunteers, randomly assigned to receive either RW94 or placebo for a period of four days when dietary fat intake was controlled. After a 10-day washout period, the randomly assigned groups were crossed over to receive placebo and RW94, respectively, for a second 4-day period, when fat intake was similarly controlled. Five grams of RW94 administered orally 30 min after each meal resulted in a statistically significant increase in the amount of excreted faecal lipids compared with placebo (p < 0.05). Following high fat intake, total blood cholesterol was predictably raised in both placebo and RW94 groups, but was less markedly raised with RW94 than placebo. All subjects lost body weight during the study, but the loss while consuming RW94 was significantly greater (p < 0.05) than while consuming placebo. All subjects found the treatments acceptable, though an increased incidence of flatulence, rumbling stomach and abdominal discomfort was noted with RW94 compared with placebo. RW94 was comparable with placebo in respect of safety.
RW94是食品工业中一种允许使用的添加剂,它在体外可使脂肪酸沉淀。在体内,这可能导致人体对脂肪酸的吸收减少,因此可能会影响粪便中脂肪的排泄量。开展了一项关于RW94对身体脂肪吸收和排泄影响的调查。在一组12名健康志愿者中,将该产品的安全性、耐受性和有效性与安慰剂进行比较,这些志愿者被随机分配,在控制膳食脂肪摄入量的情况下,接受RW94或安慰剂治疗四天。经过10天的洗脱期后,随机分组的两组交叉,分别在第二个4天期间接受安慰剂和RW94治疗,此时脂肪摄入量同样受到控制。每餐饭后30分钟口服5克RW94,与安慰剂相比,粪便脂质排泄量有统计学意义的显著增加(p< 0.05)。高脂肪摄入后,安慰剂组和RW94组的总血胆固醇均出现预期升高,但RW94组的升高幅度小于安慰剂组。在研究期间所有受试者体重均下降,但服用RW94时的体重下降幅度显著大于服用安慰剂时(p< 0.05)。所有受试者都认为这些治疗方法是可以接受的,不过与安慰剂相比,RW94组出现肠胃胀气、胃部咕噜作响和腹部不适的发生率有所增加。在安全性方面,RW94与安慰剂相当。